Physician profile
Steven Etherton
NPI 1407951734
$999.28
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $366 · 2021: $222 · 2023: $14.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $204.70 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $107.00 | 2019-2020 | |
| Lilly USA, LLC | $89.74 | 2019-2021 | |
| Mylan Specialty L.P. | $76.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.86 | 2019-2021 | |
| Pfizer INC. | $52.23 | 2019-2020 | |
| Amgen INC. | $52.13 | 2019-2021 | |
| Glaxosmithkline, LLC. | $48.26 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $47.00 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $39.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.19 | 2020-2021 | |
| Eisai INC. | $37.34 | 2020-2021 | |
| Abbvie INC. | $29.00 | 2021-2023 | |
| Astellas Pharma US INC | $26.00 | 2019-2020 | |
| Amarin Pharma, INC. | $24.49 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.14 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.91 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.00 | 2019 | |
| Allergan, INC. | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Etherton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.